Bayesian designs that make subgroup-specific decisions in randomized comparative trials or sequentially adaptive early-phase dose-finding trials are superior to designs that ignore patient ...

A phase 2/3 clinical trial of Biohaven Pharmaceutical’s troriluzole in Alzheimer’s disease has missed its co-primary endpoints. Biohaven, which slipped the news out on a federal holiday, is yet to ...